Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06559618 · ClinicalTrials.gov registry record · Phase 1
Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
A Phase 1 study of Spinal Cord Injuries and Bacteriuria, sponsored by Barbara Wells Trautner.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06559618 is a Phase 1 study of Spinal Cord Injuries and Bacteriuria that is actively recruiting participants, run by Barbara Wells Trautner. The registered enrollment target is 30 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06559618, a Phase 1 study of Spinal Cord Injuries and Bacteriuria, is actively recruiting participants, sponsored by Barbara Wells Trautner.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1b study to assess the safety, tolerability, PK, and PD of investigational phage therapy (IP) in adults with SCI and bladder colonization (ASB). It is a single-center, randomized, double-blind, placebo-controlled study in adults with SCI with neurogenic bladders and bacteriuria who use indwelling catheters, or who require intermittent catheterization for bladder drainage.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Phage Therapy
Study Locations (1)
Texas
- Michael E. DeBakey VA Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06559618
The ClinicalTrials.gov registry entry for NCT06559618 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (51% lower). The listed sponsor is Barbara Wells Trautner, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06559618 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06559618 about?
NCT06559618 is a clinical study titled "Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria". This is a Phase 1b study to assess the safety, tolerability, PK, and PD of investigational phage therapy (IP) in adults with SCI and bladder colonization (ASB). It is a single-center, randomized, double-blind, placebo-controlled study in adults with SCI with neurogenic bladders and bacteriuria who u...
What is the current status of trial NCT06559618?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-02-03. Estimated completion is 2026-12.
What conditions does trial NCT06559618 study?
This clinical trial studies the following conditions: Spinal Cord Injuries, Bacteriuria, Asymptomatic Bacteriuria, Escherichia Coli.
What interventions are being tested in trial NCT06559618?
The interventions under investigation include: Placebo (OTHER), Phage Therapy (DRUG).
Who is sponsoring clinical trial NCT06559618?
This trial is sponsored by Barbara Wells Trautner, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06559618 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NVG-291 in Spinal Cord Injury Subjects
RECRUITING · Phase 1
-
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
RECRUITING · Phase 1
-
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacological Agents for Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 1
-
Improving Functioning in Persons With Chronic Pain Post-SCI Through Virtual Classroom Education
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.